ASPIVIX – Manufacturer of non-traumatic medical devices for gynecology – closes $5M Series A+ Funding Round and receives a large EUREKA-EUROSTARS grant co-funded by Innosuisse, the Swiss Innovation Agency.
This funding round will accelerate market access in Europe and US, and finance clinical activities in the US, while the EUREKA EUROSTARS grant will fuel R&D’s activities to expand product offering.
ASPIVIX, a medical technology company focused on innovations in women’s healthcare and the maker of the new generation of non-traumatic cervix stabilizer CAREVIX™, announced today that it has raised $5 million in a Series A+ funding round. The round was led by HEMEX and was joined by existing investors 4FOx ventures and Zürcher Kantonalbank, as well as new investor LaunchPad APAC.
ASPIVIX will use this new investment to enter the market in Europe and US. Additionally, the company will invest in R&D to expand its existing product line and generate additional clinical data in the US. This will allow Aspivix to continue giving women gentler and safer access to gynecological procedures and contraception.
In addition, a EUREKA-EUROSTARS grant, co-funded by Innosuisse, will enable ASPIVIX to pursue new product development and strengthen its technological edge. “This grant will allow ASPIVIX to boost our research and materialize our goal for a Gynecology, now modern!” explained Julien Finci, co-founder, and CTO.
ASPIVIX’s vision is to empower women with gentler and safer gynecological procedures through clinically proven technologies. “The trust from our existing and new investors is a great motivation to realize our vision in women’s health and make a difference for millions of women worldwide” co-founder and CEO Mathieu Horras added.
“We are very impressed with the excellent clinical outcomes ASPIVIX has demonstrated with CAREVIX™ in gynecological procedures like intra-uterine device (IUD) insertion.” adds Pascal Winnen, CEO of Hemex AG and new Board Member at Aspivix. “We believe that the significant reduction in pain and bleeding, will allow many more women to choose this safe and efficacious method of contraception.”
“As an original investor in Aspivix, we are pleased with the progress of this company. This follow-up investment will allow the company to reach its patients and allow women to benefit from their wonderful innovations.” says Jean-Pierre Rosat, General Partner of 4FOx Ventures.
HEMEX AG is a CRO committed to changing the future of healthcare by guiding the most promising European start-ups through each and every step to bring innovative pharmaceuticals, medical devices and in vitro diagnostics to the market, mainly focusing on the United Nation’s Sustainable Development Goals (SDG) 3.4, 3.7 and 3.d. Headquartered close to the thriving Basel global Life Sciences hub, the goal at HEMEX is to ensure start-ups have access to a wide range of tailored products, practical solutions and fundraising support. This empowers the next generation of transformative discoveries to grow into successful and sustainable businesses, and drive change in both human and animal healthcare.
For more information, visit www.hemex.ch
About 4FOx Ventures:
4FOx Ventures is a Luxembourg domiciled fund, focused on early-stage companies in Switzerland. The fund invests in artificial intelligence related projects and medtech companies, with a special emphasis on ethical and highly innovative projects. The 4FOx team is composed of successful and seasoned entrepreneurs, who makes substantial efforts to support the portfolio companies in installing Good Management Practices very early on and provide networking. The fund is also engaged in the search for co-investors specialized in the industries of the portfolio companies on subsequent financing rounds. 4FOx Ventures is managed by Berger, van Berchem & Cie SA, an asset management company based in Geneva and Lausanne.
For more information, visit https://4fox-ventures.com
About Zürcher Kantonalbank:
Zürcher Kantonalbank is a leading universal bank in the Zurich economic area with Swiss roots and international reach. It is an independent, incorporated public-law institution of the Canton of Zurich and has received top ratings from the rating agencies Standard & Poor’s, Moody’s and Fitch (AAA/Aaa). With more than 5,000 employees, Zürcher Kantonalbank offers its clients a comprehensive range of products and services. The bank’s core activities include financing businesses, asset and wealth management, trading, capital market transactions, deposits, payment transactions and the card business. Zürcher Kantonalbank provides clients and distribution partners with a comprehensive range of investment and retirement provision products and services.
Share this story: